FindMyKOL
Clinical trialNCT00288119RecruitingObservational

Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

NCT00288119 is an observational study sponsored by Case Western Reserve University. As of 21 Nov 2026, it is recruiting participants. It studies Barrett's Esophagus and Esophageal Neoplasm. The registry lists an enrollment of 2,000 participants at 10 sites in 1 country. The registry lists a start date of 1 Oct 2005 and a primary completion date of 31 Jul 2028. One of its registered investigators has a FindMyKOL profile.

SponsorCase Western Reserve University →Enrollment2,000Barrett's EsophagusEsophageal Neoplasm
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00288119
FieldValue
Registry IDNCT00288119
StatusRecruiting
Study typeObservational study
Lead sponsorCase Western Reserve University
Enrollment2,000
Registered sites10
Countries1
ConditionsBarrett's Esophagus and Esophageal Neoplasm
Start1 Oct 2005
Primary completion31 Jul 2028
Study completion31 Jul 2028
Last update posted10 Aug 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The overall objectives of this BETRNet Research Center (RC) are: 1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA) 2. to increase the biological understanding of key observations made by our clinical researchers; 3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent EAC and improve the outcomes of EAC; 4. to foster a transdisciplinary and translation research culture and to effectively expand and enhance scientific research focused on BE and EAC; 5. to evaluate research and transdisciplinary programs and to continuously improve research, productivity and enhance translational implementation. These objectives build and synergize on existing multi-institutional collaborative networks and the considerable clinical, basic science, and translational expertise available at our institutions, focusing on improving the outcomes of patients with BE and EAC. The overarching organization framework for this RC proposal is 1) to focus laboratory research on understanding the genetic susceptibility, genomic and epigenetic changes that influence the development of BE and EAC; and 2) to then translate laboratorydiscoveries into clinical applications for effective detection, molecular risk stratification, and prevention of progression from BE to EAC.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Maryland, United States1 site, 1 recruiting
  • Johns Hopkins Hospital

    Baltimore

    Marcia I Canto, M.D.
    Recruiting
Minnesota, United States1 site, 1 recruiting
  • Mayo Clinic

    Rochester

    Ganapathy A Prasad, M.D.
    Recruiting
Missouri, United States1 site, 1 recruiting
  • Washington University School of Medicine

    St Louis

    Jean Wang, MD
    Recruiting
New York, United States1 site, 1 recruiting
  • Columbia University Medical Center

    New York

    Julian Abrams, MD
    Recruiting
North Carolina, United States1 site, 1 recruiting
  • University of North Carolina at Chapel Hill

    Chapel Hill

    Nicholas J Shaheen, M.D.
    Recruiting
Ohio, United States2 sites, 2 recruiting
  • Cleveland Clinic

    Cleveland

    Prashanthi Thota, MD
    Recruiting
  • University Hospitals of Cleveland

    Cleveland

    Amitabh Chak, MD →John Dumot, MD
    Recruiting
Pennsylvania, United States1 site, 1 recruiting
  • University of Pennsylvania

    Philadelphia

    Gary W. Falk, MD, MS
    Recruiting
Washington, United States2 sites, 2 recruiting
  • Fred Hutchinson Cancer Research Center, Uwmc

    Seattle

    Kaz Andrew, MDWilliam Grady, MD
    Recruiting
  • Va Puget Sound Health Care System

    Seattle

    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashington: 2 sites, 2 recruitingWA2MontanaMTNorth DakotaNDMinnesota: 1 site, 1 recruitingMN1WisconsinWIMichiganMINew York: 1 site, 1 recruitingNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhio: 2 sites, 2 recruitingOH2Pennsylvania: 1 site, 1 recruitingPA1New JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouri: 1 site, 1 recruitingMO1KentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 site, 1 recruitingMD1DelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth Carolina: 1 site, 1 recruitingNC1South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT00288119

Each answer restates registry values shown on this page.

What is NCT00288119?

NCT00288119 is an observational study sponsored by Case Western Reserve University. It studies Barrett's Esophagus and Esophageal Neoplasm.

Is NCT00288119 recruiting?

As of 21 Nov 2026, it is recruiting participants. 10 of its 10 sites list their own status as recruiting.

Who leads NCT00288119?

The registry names Amitabh Chak, MD (principal investigator, University Hospitals Cleveland Medical Center, CWRU, Cleveland, OH), Andrew Kaz, MD (principal investigator, VA Puget Sound Health Care System), Ganapathy Prasad, M.D. (principal investigator, Mayo Clinic) and 8 more officials as overall officials.

Where does NCT00288119 run?

The registry lists 10 sites in 1 country. Every site with a stated country is in one country: United States.

When is NCT00288119 expected to complete?

The registry lists a primary completion date of 31 Jul 2028 and a study completion date of 31 Jul 2028. The sponsor last updated the record on 10 Aug 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.